NCT02853617View on ClinicalTrials.gov

A Study of AV0328 Administered to Healthy Adult Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 22, 2017

Primary Completion Date

April 23, 2018

Study Completion Date

April 23, 2018

Conditions
PNAG-expressing Pathogenic Microbes Vaccine
Interventions
BIOLOGICAL

AV0328 - Cohort 1

Cohort 1 will receive 15 µg to be given as an IM injection

BIOLOGICAL

AV0328 - Cohort 2

Cohort 2 will receive 30 µg to be given as an IM injection

BIOLOGICAL

AV0328 - Cohort 3

Cohort 3 will receive 75 µg to be given as an IM injection

BIOLOGICAL

AV0328 - Cohort 4

Cohort 4 will receive 150 µg to be given as an IM injection

Trial Locations (1)

07753

Inflamax Research, Inc., Neptune City

All Listed Sponsors
lead

Alopexx Vaccine, LLC

INDUSTRY

NCT02853617 - A Study of AV0328 Administered to Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter